STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive?

PD-1/PD-L1 inhibitor monotherapy or in combination with chemotherapy as upfront treatment for advanced NSCLC with PD-L1 expression ≥ 50%: Selecting the best strategy

(2021) Alessandro Di Federico et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

P14.26 Diminished Efficacy of PD-(L)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma is Impacted by KRAS Mutation Status

(2021) B. Ricciuti et al.   Journal of Thoracic Oncology

Baseline plasma tumor mutation burden predicts response to pembrolizumab-based therapy in patients with metastatic non-small cell lung cancer

(2020) Charu Aggarwal et al.   CLINICAL CANCER RESEARCH

First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status

(2020) Francesco Facchinetti et al.   EUROPEAN JOURNAL OF CANCER

KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden

(2020) D. Marinelli et al.   ANNALS OF ONCOLOGY

Concurrent Mutations in STK11 and KEAP1 Promote Ferroptosis Protection and SCD1 Dependence in Lung Cancer

(2020) Corrin A. Wohlhieter et al.   Cell Reports

Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11

(2019) Linnéa La Fleur et al.   LUNG CANCER

Predicting Response to Cancer Immunotherapy using Non-invasive Radiomic Biomarkers

(2019) S Trebeschi et al.   ANNALS OF ONCOLOGY

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

(2019) J Mazières et al.   ANNALS OF ONCOLOGY

Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes

(2019) Jacqueline V. Aredo et al.   LUNG CANCER

The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity

(2019) Chengming Liu et al.   CANCER LETTERS

TP53,STK11andEGFRMutations Predict Tumor Immune Profile and the Response to anti-PD-1 in Lung Adenocarcinoma

(2018) Jerome Biton et al.   CLINICAL CANCER RESEARCH

Clinical and Pathological Characteristics ofKEAP1- andNFE2L2-Mutated Non–Small Cell Lung Carcinoma (NSCLC)

(2018) Rieke Frank et al.   CLINICAL CANCER RESEARCH

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

(2018) Marina Chiara Garassino et al.   LANCET ONCOLOGY

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

(2018) Leena Gandhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma

(2018) Ferdinandos Skoulidis et al.   Cancer Discovery

Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

(2018) David R. Gandara et al.   NATURE MEDICINE

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy

(2018) Razvan Cristescu et al.   SCIENCE

LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value

(2017) Francesco Facchinetti et al.   LUNG CANCER

STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment

(2016) S. Koyama et al.   CANCER RESEARCH

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: Implication to cancer cell resistance

(2007) Jeong-Min Cho et al.   CANCER LETTERS